Cargando…
p75 neurotrophin receptor and pro-BDNF promote cell survival and migration in clear cell renal cell carcinoma
p75(NTR), a member of TNF receptor family, is the low affinity receptor common to several mature neurotrophins and the high affinity receptor for pro-neurotrophins. Brain-Derived Neurotrophic Factor (BDNF), a member of neurotrophin family has been described to play an important role in development a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085170/ https://www.ncbi.nlm.nih.gov/pubmed/27120782 http://dx.doi.org/10.18632/oncotarget.8911 |
Sumario: | p75(NTR), a member of TNF receptor family, is the low affinity receptor common to several mature neurotrophins and the high affinity receptor for pro-neurotrophins. Brain-Derived Neurotrophic Factor (BDNF), a member of neurotrophin family has been described to play an important role in development and progression of several cancers, through its binding to a high affinity tyrosine kinase receptor B (TrkB) and/or p75(NTR). However, the functions of these two receptors in renal cell carcinoma (RCC) have never been investigated. An overexpression of p75(NTR), pro-BDNF, and to a lesser extent for TrkB and sortilin, was detected by immunohistochemistry in a cohort of 83 clear cell RCC tumors. p75(NTR), mainly expressed in tumor tissues, was significantly associated with higher Fuhrman grade in multivariate analysis. In two derived-RCC lines, 786-O and ACHN cells, we demonstrated that pro-BDNF induced cell survival and migration, through p75(NTR) as provided by p75(NTR) RNA silencing or blocking anti-p75(NTR) antibody. This mechanism is independent of TrkB activation as demonstrated by k252a, a tyrosine kinase inhibitor for Trk neurotrophin receptors. Taken together, these data highlight for the first time an important role for p75(NTR) in renal cancer and indicate a putative novel target therapy in RCC. |
---|